These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33899154)

  • 1. Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters.
    Stolte B; Nonnemacher M; Kizina K; Bolz S; Totzeck A; Thimm A; Wagner B; Deuschl C; Kleinschnitz C; Hagenacker T
    J Neurol; 2021 Dec; 268(12):4667-4679. PubMed ID: 33899154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen.
    Zhu X; Li H; Hu C; Wu M; Zhou S; Wang Y; Li W
    BMC Pediatr; 2024 Jul; 24(1):474. PubMed ID: 39054521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
    Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST
    Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.
    Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O
    J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
    Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
    Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients.
    Müschen LH; Osmanovic A; Binz C; Jendretzky KF; Ranxha G; Bronzlik P; Abu-Fares O; Wiehler F; Möhn N; Hümmert MW; Gingele S; Götz F; Stangel M; Skripuletz T; Schreiber-Katz O; Petri S
    Brain Sci; 2021 Feb; 11(3):. PubMed ID: 33652830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
    Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
    Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
    Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.
    Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R
    Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen.
    Wurster CD; Koch JC; Cordts I; Dreyhaupt J; Otto M; Uzelac Z; Witzel S; Winter B; Kocak T; Schocke M; Weydt P; Wollinsky K; Ludolph AC; Deschauer M; Lingor P; Tumani H; Hermann A; Günther R
    Front Neurol; 2019; 10():1179. PubMed ID: 31787927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.